A Multi-Center Study Investigating the Correlation Between TARCEVA-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy

Trial Profile

A Multi-Center Study Investigating the Correlation Between TARCEVA-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 30 May 2017 Status changed from active, no longer recruiting to completed.
    • 02 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 02 Apr 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top